What is Cerevance?
Cerevance is a private, clinical-stage pharmaceutical company headquartered in Boston, Massachusetts, dedicated to transforming the treatment landscape for brain-related disorders. The company distinguishes itself through the application of its proprietary NETSseq technology, which allows researchers to reveal transcriptional and epigenetic differences between specific cell types in human brains spanning nine decades of age. By focusing on the molecular architecture of the aging brain, Cerevance aims to identify and validate high-potential therapeutic targets that have historically remained elusive to traditional drug discovery methods. Its market position is defined by the intersection of big data analytics and advanced neurobiology, positioning the firm as a critical player in the development of next-generation therapies for neurodegenerative and psychiatric diseases.
How much funding has Cerevance raised?
Cerevance has raised a total of $204.5M across 4 funding rounds:
Series A
$21.5M
Series B
$116M
Other Financing Round
$47M
Series C
$20M
Series A (2016): $21.5M with participation from Lightstone Ventures launched and Takeda Pharmaceutical Company
Series B (2023): $116M led by GV, Dementia Discovery Fund, UPMC, Lightstone Ventures, Bill Gates, Casdin Capital, Foresite Capital, Dolby Family Ventures, and Takeda
Other Financing Round (2024): $47M supported by Agent Capital
Series C (2026): $20M featuring Lightstone Ventures, Double Point Ventures, GV, and Gates Frontier
Key Investors in Cerevance
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors. The company focuses on enterprise solutions, life sciences, consumer products, and frontier technology innovations.
Lightstone Ventures
Lightstone Ventures backs founders turning cutting edge science into new therapies and medical technologies. Its team partners closely with biotech and medtech leaders, providing capital, insight and connections.
Double Point Ventures
Double Point Ventures is a venture capital firm focused on investing in innovative healthcare companies that are shaping the future of medicine, specializing in therapeutics, diagnostics, and digital health.
What's next for Cerevance?
With the successful closure of this latest financing round, Cerevance is well-positioned to accelerate its clinical development pipeline and expand the reach of its NETSseq platform. The strategic focus will likely shift toward advancing lead candidates into later-stage clinical trials while simultaneously deepening the company's proprietary database of human brain cell data. As the firm matures, the emphasis will remain on translating complex biological insights into actionable medical interventions, potentially setting the stage for future partnerships or commercialization efforts. The continued backing from top-tier venture firms underscores the long-term potential of Cerevance to redefine the standard of care in neurology through precision-driven pharmaceutical innovation.
See full Cerevance company page
